Artia Global Partners LP Takes Position in ProKidney Corp. $PROK

Artia Global Partners LP bought a new stake in ProKidney Corp. (NASDAQ:PROK) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 1,838,411 shares of the company’s stock, valued at approximately $4,118,000. ProKidney makes up 0.6% of Artia Global Partners LP’s investment portfolio, making the stock its 27th biggest position. Artia Global Partners LP owned approximately 0.61% of ProKidney as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. State Street Corp raised its stake in ProKidney by 1.1% during the fourth quarter. State Street Corp now owns 480,345 shares of the company’s stock worth $1,076,000 after acquiring an additional 5,388 shares during the period. Squarepoint Ops LLC raised its stake in ProKidney by 2.0% during the fourth quarter. Squarepoint Ops LLC now owns 351,421 shares of the company’s stock worth $787,000 after acquiring an additional 6,845 shares during the period. Cetera Investment Advisers acquired a new stake in ProKidney during the fourth quarter worth about $28,000. ExodusPoint Capital Management LP raised its stake in ProKidney by 22.8% during the fourth quarter. ExodusPoint Capital Management LP now owns 128,853 shares of the company’s stock worth $289,000 after acquiring an additional 23,924 shares during the period. Finally, AQR Capital Management LLC raised its stake in ProKidney by 106.4% during the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock worth $46,000 after acquiring an additional 27,098 shares during the period. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Trading Up 3.6%

Shares of NASDAQ:PROK opened at $1.75 on Thursday. The firm’s 50 day moving average is $1.83 and its two-hundred day moving average is $2.05. ProKidney Corp. has a 52 week low of $0.54 and a 52 week high of $7.13. The firm has a market capitalization of $528.61 million, a P/E ratio of -3.30 and a beta of 1.64.

ProKidney (NASDAQ:PROK) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.10 million. Analysts predict that ProKidney Corp. will post -0.49 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PROK shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProKidney in a research note on Tuesday, April 21st. Jefferies Financial Group upgraded shares of ProKidney to a “strong-buy” rating in a research note on Wednesday, March 18th. Wall Street Zen lowered shares of ProKidney from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of ProKidney in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.40.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.